Novel monoclonal antibody-based therapies for acute myeloid leukemia
LM Morsink, RB Walter - Best Practice & Research Clinical Haematology, 2019 - Elsevier
There has been long-standing interest in using monoclonal antibodies to improve outcomes
of people with acute myeloid leukemia (AML). While several candidate therapeutics have
failed at various stages of clinical testing, improved survival of some patients receiving the
CD33 antibody-drug conjugate gemtuzumab ozogamicin has provided first evidence that
monoclonal antibodies have a role in the armamentarium against AML. Over the last several
years, work to improve the success of monoclonal antibody-based therapies in AML has …
of people with acute myeloid leukemia (AML). While several candidate therapeutics have
failed at various stages of clinical testing, improved survival of some patients receiving the
CD33 antibody-drug conjugate gemtuzumab ozogamicin has provided first evidence that
monoclonal antibodies have a role in the armamentarium against AML. Over the last several
years, work to improve the success of monoclonal antibody-based therapies in AML has …
